Share

[{"d":"2024-09-05","n":"Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference","u":"/media/press-releases/2024/hansa-biopharma-to-participate-in-h-c-wainwright-26th-annual-global-investment-conference/"},{"d":"2024-02-22","n":"Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer","u":"/media/press-releases/2024/evan-ballantyne-to-join-hansa-biopharma-as-chief-financial-officer/"},{"d":"2024-05-27","n":"Notice to Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2024/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2024-01-06","n":"Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference","u":"/media/press-releases/2024/hansa-biopharma-provides-update-on-business-and-key-financials-ahead-of-the-jp-morgan-healthcare-conference/"},{"d":"2024-03-21","n":"Hansa Biopharma publishes 2023 Annual and Sustainability Reports","u":"/media/press-releases/2024/hansa-biopharma-publishes-2023-annual-and-sustainability-reports/"},{"d":"2024-04-12","n":"Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)","u":"/media/press-releases/2024/hansa-biopharma-announces-successful-execution-of-a-directed-share-issue-of-sek-372-million-usd-34-6-million/"},{"d":"2024-05-03","n":"Hansa Biopharma: increase in number of shares and votes","u":"/media/press-releases/2024/hansa-biopharma-increase-in-number-of-shares-and-votes-20240503/"},{"d":"2024-02-02","n":"Hansa Biopharma Year-end report January-December 2023","u":"/media/press-releases/2024/hansa-biopharma-year-end-report-january-december-2023/"},{"d":"2024-04-02","n":"Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance","u":"/media/press-releases/2024/hansa-biopharma-expects-strong-first-quarter-2024-sales-performance/"},{"d":"2024-04-18","n":"Hansa Biopharma interim report January-March 2024","u":"/media/press-releases/2024/hansa-biopharma-interim-report-january-march-2024/"},{"d":"2024-05-03","n":"Correction: Hansa Biopharma: increase in number of shares and votes","u":"/media/press-releases/2024/correction-hansa-biopharma-increase-in-number-of-shares-and-votes-20240503/"},{"d":"2024-06-07","n":"Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm","u":"/media/press-releases/2024/hansa-biopharma-publishes-prospectus-for-admission-to-trading-of-shares-on-nasdaq-stockholm/"},{"d":"2024-10-03","n":"Hansa Biopharma to host Q3 2024 interim results conference call","u":"/media/press-releases/2024/hansa-biopharma-to-host-q3-2024-interim-results-conference-call/"},{"d":"2024-10-07","n":"Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial","u":"/media/press-releases/2024/hansa-biopharmas-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more-than-95-and-clear-redosing-potential-in-first-in-human-trial/"},{"d":"2024-10-17","n":"Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results","u":"/media/press-releases/2024/hansa-biopharma-reports-third-quarter-and-interim-january--september-2024-financial-results/"},{"d":"2024-10-30","n":"Hansa Biopharma to Attend Truist Securities BioPharma Symposium","u":"/media/press-releases/2024/hansa-biopharma-to-attend-truist-securities-biopharma-symposium/"},{"d":"2024-11-13","n":"Hansa Biopharma to Attend Jefferies London Healthcare Conference","u":"/media/press-releases/2024/hansa-biopharma-to-attend-jefferies-london-healthcare-conference/"},{"d":"2024-08-23","n":"Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis","u":"/media/press-releases/2024/hansa-biopharma-announces-departure-of-chief-commercial-officer-matthew-shaulis/"},{"d":"2024-05-31","n":"Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial","u":"/media/press-releases/2024/hansa-biopharma-completes-randomization-in-pivotal-phase-3-us-confides-trial/"},{"d":"2024-05-21","n":"Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting","u":"/media/press-releases/2024/hansa-biopharma-to-present-data-at-2024-american-transplant-congress-annual-meeting/"},{"d":"2024-07-18","n":"Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update","u":"/media/press-releases/2024/hansa-biopharma-reports-second-quarter-2024-financial-results-and-business-update/"},{"d":"2024-07-03","n":"Hansa Biopharma to host Q2 2024 interim results conference call","u":"/media/press-releases/2024/hansa-biopharma-to-host-q2-2024-interim-results-conference-call/"},{"d":"2024-06-28","n":"Hansa Biopharma: increase in number of shares and votes","u":"/media/press-releases/2024/hansa-biopharma-increase-in-number-of-shares-and-votes/"},{"d":"2024-06-27","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2024/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2023-02-02","n":"Hansa Biopharma Year-end report January-December 2022","u":"/media/press-releases/2023/hansa-biopharma-year-end-report-january-december-2022/"},{"d":"2023-03-31","n":"Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)","u":"/media/press-releases/2023/hansa-biopharma-completes-enrollment-in-phase-2-study-of-imlifidase-in-guillain-barre-syndrome-gbs/"},{"d":"2023-01-02","n":"Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic","u":"/media/press-releases/2023/hansa-biopharma-announces-positive-reimbursement-decision-for-idefirix-imlifidase-in-the-czech-republic/"},{"d":"2023-01-20","n":"Hansa Biopharma to host conference call to provide Year-end 2022 results and a Business Update","u":"/media/press-releases/2023/hansa-biopharma-to-host-conference-call-to-provide-year-end-2022-results-and-a-business-update/"},{"d":"2023-03-29","n":"Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation","u":"/media/press-releases/2023/hansa-biopharma-announces-positive-reimbursement-decision-in-spain-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation/"},{"d":"2023-03-30","n":"Hansa Biopharma publishes Annual Report 2022","u":"/media/press-releases/2023/hansa-biopharma-publishes-annual-report-2022/"},{"d":"2023-04-14","n":"Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update","u":"/media/press-releases/2023/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-march-2023-and-a-business-update/"},{"d":"2023-04-20","n":"Hansa Biopharma interim report January–March 2023","u":"/media/press-releases/2023/hansa-biopharma-interim-report-januarymarch-2023/"},{"d":"2023-01-30","n":"Hansa Biopharma announces planned departure of Chief Scientific Officer Christian Kjellman","u":"/media/press-releases/2023/hansa-biopharma-announces-planned-departure-of-chief-scientific-officer-christian-kjellman/"},{"d":"2023-03-03","n":"Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma","u":"/media/press-releases/2023/matthew-shaulis-appointed-chief-commercial-officer-and-us-president-of-hansa-biopharma/"},{"d":"2023-04-27","n":"Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies","u":"/media/press-releases/2023/hansa-biopharma-and-genethon-announce-collaboration-to-develop-imlifidase-as-pre-treatment-to-gene-therapy-in-crigler-najjar-syndrome-patients-with-anti-aav-antibodies/"},{"d":"2023-06-01","n":"Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation","u":"/media/press-releases/2023/hansa-biopharma-announces-positive-reimbursement-decision-for-idefirix-imlifidase-in-belgium-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation/"},{"d":"2023-07-04","n":"Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials","u":"/media/press-releases/2023/hansa-biopharma-ab-recognizes-a-write-up-of-sek-1430-billion-in-intangible-assets-related-to-idefirix-in-the-financial-statements-of-the-parent-company---no-impact-on-the-consolidated-financials/"},{"d":"2023-07-06","n":"Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update","u":"/media/press-releases/2023/hansa-biopharma-to-host-conference-call-to-provide-half-year-results-for-january-june-2023-and-a-business-update/"},{"d":"2023-10-17","n":"Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study","u":"/media/press-releases/2023/imlifidase-demonstrated-90-patient-survival-and-82-graft-survival-at-five-years-in-extended-pooled-analysis-with-data-from-17-hmedides-14-study/"},{"d":"2023-11-27","n":"Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota","u":"/media/press-releases/2023/hansa-biopharma-announces-planned-departure-of-chief-financial-officer-donato-spota/"},{"d":"2023-12-05","n":"Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables","u":"/media/press-releases/2023/hansa-biopharma-plans-restructuring-to-strengthen-long-term-competitiveness-and-advance-key-deliverables/"},{"d":"2023-07-11","n":"Idefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantation","u":"/media/press-releases/2023/idefirix-imlifidase-receives-provisional-approval-in-australia-as-desensitization-treatment-in-highly-sensitized-patients-prior-to-kidney-transplantation/"},{"d":"2023-07-31","n":"Hansa Biopharma: Increase of the number of votes","u":"/media/press-releases/2023/hansa-biopharma-increase-of-the-number-of-votes/"},{"d":"2023-05-29","n":"Notice to Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2023/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2023-05-30","n":"Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease","u":"/media/press-releases/2023/hansa-announces-first-patient-dosed-with-imlifidase-in-a-global-pivotal-phase-3-trial-in-anti-glomerular-basement-membrane-anti-gbm-disease/"},{"d":"2023-09-01","n":"Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma","u":"/media/press-releases/2023/dr-hitto-kaufmann-appointed-chief-scientific-officer-of-hansa-biopharma/"},{"d":"2023-12-13","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2023/hansa-biopharma-nomination-committee-formed/"},{"d":"2023-10-26","n":"Hansa Biopharma Interim Report January-September 2023","u":"/media/press-releases/2023/hansa-biopharma-interim-report-january-september-2023/"},{"d":"2023-12-07","n":"Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)","u":"/media/press-releases/2023/imlifidase-demonstrated-positive-safety-tolerability-and-early-efficacy-outcomes-in-15-hmedides-09-phase-2-trial-in-guillain-barre-syndrome-gbs/"},{"d":"2023-12-14","n":"Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation","u":"/media/press-releases/2023/imlifidase-met-primary-endpoint-in-16-hmedides-12-phase-2-trial-in-patients-with-amr-following-kidney-transplantation/"},{"d":"2023-06-29","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2023/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2023-07-19","n":"First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis","u":"/media/press-releases/2023/first-patient-treated-with-imlifidase-in-an-investigator-initiated-phase-2-study-in-anca-associated-vasculitis/"},{"d":"2023-07-20","n":"Hansa Biopharma half year report 2023","u":"/media/press-releases/2023/hansa-biopharma-half-year-report-2023/"},{"d":"2023-10-09","n":"Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487","u":"/media/press-releases/2023/hansa-biopharma-announces-encouraging-high-level-results-for-first-in-human-trial-of-hnsa-5487/"},{"d":"2023-10-11","n":"Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients","u":"/media/press-releases/2023/update-on-confides-phase-3-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-09-12","n":"The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/the-scottish-medicines-consortium-smc-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-12-08","n":"Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation","u":"/media/press-releases/2022/hansa-biopharma-announces-positive-reimbursement-decision-in-italy-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation/"},{"d":"2022-08-22","n":"Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-and-medison-pharma-announce-positive-reimbursement-decision-in-poland-for-idefirix-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-09-30","n":"Hansa Biopharma: Increase of the number of shares and votes","u":"/media/press-releases/2022/hansa-biopharma-increase-of-the-number-of-shares-and-votes/"},{"d":"2022-10-20","n":"Hansa Biopharma Interim report January-September 2022","u":"/media/press-releases/2022/hansa-biopharma-interim-report-january-september-2022/"},{"d":"2022-11-02","n":"Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta’s SRP-9001 gene therapy in DMD in 2023","u":"/media/press-releases/2022/hansa-biopharma-and-partner-sarepta-therapeutics-plan-to-initiate-a-clinical-study-with-imlifidase-as-a-pre-treatment-to-sareptas-srp-9001-gene-therapy-in-dmd-in-2023/"},{"d":"2022-11-28","n":"Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation","u":"/media/press-releases/2022/hansa-biopharma-announces-positive-topline-data-from-the-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation/"},{"d":"2022-12-23","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2022/hansa-biopharma-nomination-committee-formed/"},{"d":"2022-12-30","n":"Hansa Biopharma: Increase of the number of shares and votes","u":"/media/press-releases/2022/hansa-biopharma-increase-of-the-number-of-shares-and-votes-2022-12-30/"},{"d":"2022-09-30","n":"Hansa Biopharma achieves Great Place to Work® certification for the third consecutive year","u":"/media/press-releases/2022/hansa-biopharma-achieves-great-place-to-work-certification-for-the-third-consecutive-year/"},{"d":"2022-12-28","n":"Correction: Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2022/correction-hansa-biopharma-nomination-committee-formed/"},{"d":"2022-09-09","n":"Hansa Biopharma: Issue and repurchase of class C shares for incentive programs","u":"/media/press-releases/2022/hansa-biopharma-issue-and-repurchase-of-class-c-shares-for-incentive-programs/"},{"d":"2022-09-30","n":"Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2022-and-business-update/"},{"d":"2022-10-31","n":"Hansa Biopharma: Increase of the number of shares and votes","u":"/media/press-releases/2022/hansa-biopharma-increase-of-the-number-of-shares-and-votes-2022-10-31/"},{"d":"2022-08-10","n":"European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International","u":"/media/press-releases/2022/european-society-for-organ-transplantations-esot-guidelines-for-desensitization-treatment-of-highly-sensitized-kidney-transplant-patients-published-in-transplant-international/"},{"d":"2022-07-19","n":"Hansa Biopharma half year report 2022","u":"/media/press-releases/2022/hansa-biopharma-half-year-report-2022/"},{"d":"2022-07-18","n":"Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform","u":"/media/press-releases/2022/hansa-biopharma-announces-70-million-non-dilutive-product-finance-transaction-with-novaquest-to-support-continued-development-of-the-companys-antibody-cleaving-enzyme-technology-platform/"},{"d":"2022-07-11","n":"Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-announces-first-patient-treated-in-the-post-authorization-efficacy-study-paes-of-idefirix-imlifidase-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-06-30","n":"Increase of the number of votes in Hansa Biopharma","u":"/media/press-releases/2022/increase-of-the-number-of-votes-in-hansa-biopharma/"},{"d":"2022-06-30","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2022/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2022-06-30","n":"Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-half-year-results-for-january-june-2022-and-business-update/"},{"d":"2022-06-16","n":"NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/nice-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-05-30","n":"Hansa Biopharma: Notice to Annual General Meeting","u":"/media/press-releases/2022/hansa-biopharma-notice-to-annual-general-meeting/"},{"d":"2022-05-30","n":"The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022","u":"/media/press-releases/2022/the-nomination-committee-in-hansa-biopharma-proposes-peter-nicklin-as-new-chair-of-the-board-of-directors-at-the-annual-general-meeting-2022/"},{"d":"2022-05-23","n":"Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation","u":"/media/press-releases/2022/hansa-biopharma-completes-enrollment-in-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation/"},{"d":"2022-05-13","n":"Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix® (imlifidase) in kidney transplantation","u":"/media/press-releases/2022/hansa-biopharma-announces-temporary-marketing-authorization-in-switzerland-for-idefirix-imlifidase-in-kidney-transplantation/"},{"d":"2022-04-21","n":"Hansa Biopharma interim report January – March 2022","u":"/media/press-releases/2022/hansa-biopharma-interim-report-january--march-2022/"},{"d":"2022-04-20","n":"Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-granted-added-benefit-asmr-3-by-french-transparency-commission-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-04-19","n":"Hansa Biopharma announces U.S. FDA acceptance of Investigational New Drug (IND) application for Phase 3 study of imlifidase in anti-GBM disease","u":"/media/press-releases/2022/hansa-biopharma-announces-us-fda-acceptance-of-investigational-new-drug-ind-application-for-phase-3-study-of-imlifidase-in-anti-gbm-disease/"},{"d":"2022-04-08","n":"Hansa Biopharma to host conference call to provide interim results for January-March 2022 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-march-2022-and-business-update/"},{"d":"2022-04-07","n":"Hansa Biopharma publishes Annual Report 2021","u":"/media/press-releases/2022/hansa-biopharma-publishes-annual-report-2021/"},{"d":"2022-03-28","n":"Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix® (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-and-medison-pharma-announce-marketing-authorization-in-israel-for-idefirix-imlifidase-for-desensitization-treatment-of-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-03-15","n":"Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-and-german-payer-head-association-agree-on-reimbursement-price-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-03-08","n":"Key data demonstrating the potential of Hansa Biopharma’s imlifidase to significantly alter course of anti-GBM disease published in JASN","u":"/media/press-releases/2022/key-data-demonstrating-the-potential-of-hansa-biopharmas-imlifidase-to-significantly-alter-course-of-anti-gbm-disease-published-in-jasn/"},{"d":"2022-02-25","n":"Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-announces-positive-early-access-decision-by-french-haute-autorite-de-sante-to-use-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-02-03","n":"Hansa Biopharma year-end report 2021","u":"/media/press-releases/2022/hansa-biopharma-year-end-report-2021/"},{"d":"2022-01-20","n":"Hansa Biopharma to host conference call to provide Year-End report for 2021 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-for-2021-and-business-update/"},{"d":"2022-01-09","n":"Hansa Biopharma provides business update including certain key financials","u":"/media/press-releases/2022/hansa-biopharma-provides-business-update-including-certain-key-financials/"},{"d":"2022-01-03","n":"Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease","u":"/media/press-releases/2022/hansa-biopharma-enters-into-agreement-with-askbio-to-evaluate-feasibility-of-imlifidase-as-pre-treatment-ahead-of-gene-therapy-in-pompe-disease/"},{"d":"2022-12-13","n":"Hansa Biopharma announces successful execution of a directed share issue of SEK 416 million (~USD 40 million)","u":"/media/press-releases/2022/hansa-biopharma-announces-successful-execution-of-a-directed-share-issue/"},{"d":"2021-12-30","n":"Increase of the number of shares and votes in Hansa Biopharma AB","u":"/media/press-releases/2021/increase-of-the-number-of-shares-and-votes-in-hansa-biopharma-ab/"},{"d":"2021-12-29","n":"Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-enrolls-first-patient-in-us-randomized-controlled-pivotal-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-12-09","n":"Hansa Biopharma: Issue and repurchase of class C shares for incentive programs","u":"/media/press-releases/2021/hansa-biopharma-issue-and-repurchase-of-class-c-shares-for-incentive-programs/"},{"d":"2021-12-07","n":"Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel","u":"/media/press-releases/2021/hansa-biopharma-and-medison-pharma-announce-multiregional-commercialization-partnership-for-hansas-desensitization-treatment-for-kidney-transplant-in-central-eastern-europe-and-israel/"},{"d":"2021-11-15","n":"Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA","u":"/media/press-releases/2021/hansa-biopharma-to-initiate-phase-3-study-of-imlifidase-to-treat-anti-glomerular-basement-membrane-anti-gbm-disease-after-successful-pre-ind-meeting-with-us-fda/"},{"d":"2021-11-12","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2021/hansa-biopharma-nomination-committee-formed/"},{"d":"2021-11-08","n":"Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO","u":"/media/press-releases/2021/hansa-biopharma-announces-it-has-confidentially-submitted-a-draft-registration-statement-on-form-f-1-to-the-us-sec-relating-to-a-potential-us-ipo/"},{"d":"2021-10-21","n":"Hansa Biopharma interim report Jan-Sept 2021","u":"/media/press-releases/2021/hansa-biopharma-interim-report-jan-sept-2021/"},{"d":"2021-10-07","n":"Hansa Biopharma to host conference call to provide interim results for January-September 2021 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2021-and-business-update/"},{"d":"2021-09-01","n":"Hansa Biopharma presented new data on imlifidase at the European Society for Organ Transplantation (ESOT) Congress","u":"/media/press-releases/2021/hansa-biopharma-presented-new-data-on-imlifidase-at-the-european-society-for-organ-transplantation-esot-congress/"},{"d":"2021-08-31","n":"Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar","u":"/media/press-releases/2021/hansa-biopharma-announces-participation-in-fall-investor-conferences-and-provides-updated-financial-calendar/"},{"d":"2021-08-25","n":"Hansa Biopharma achieves Great Place to Work certification for second consecutive year","u":"/media/press-releases/2021/hansa-biopharma-achieves-great-place-to-work-certification-for-second-consecutive-year/"},{"d":"2021-08-02","n":"Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-announces-reimbursement-in-the-netherlands-of-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-07-15","n":"Hansa Biopharma interim report Jan-June 2021","u":"/media/press-releases/2021/hansa-biopharma-interim-report-jan-june-2021/"},{"d":"2021-07-09","n":"Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation","u":"/media/press-releases/2021/hansa-biopharma-announces-long-term-follow-up-data-demonstrating-3-year-graft-survival-of-84-after-imlifidase-treatment-and-transplantation/"},{"d":"2021-07-01","n":"Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-first-half-2021-and-business-update/"},{"d":"2021-06-28","n":"Hansa Biopharma announces decision by Swedish New Therapies Council to recommend use of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-announces-decision-by-swedish-new-therapies-council-to-recommend-use-of-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-06-23","n":"Hansa Biopharma announces study design for a US randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-announces-study-design-for-a-us-randomized-controlled-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-05-12","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2021/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2021-04-22","n":"Hansa Biopharma interim report Jan-Mar 2021","u":"/media/press-releases/2021/hansa-biopharma-interim-report-jan-mar-2021/"},{"d":"2021-04-14","n":"Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-from-q1-2021-and-business-update/"},{"d":"2021-04-09","n":"Hansa Biopharma: Notice to Annual General Meeting","u":"/media/press-releases/2021/hansa-biopharma-notice-to-annual-general-meeting/"},{"d":"2021-04-08","n":"Hansa Biopharma publishes Annual Report 2020","u":"/media/press-releases/2021/hansa-biopharma-publishes-annual-report-2020/"},{"d":"2021-03-29","n":"Hansa Biopharma enters preclinical research collaboration with argenx","u":"/media/press-releases/2021/hansa-biopharma-enters-preclinical-research-collaboration-with-argenx/"},{"d":"2021-03-01","n":"Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development","u":"/media/press-releases/2021/hansa-biopharma-appoints-dr-magnus-korsgren-as-head-of-research--development/"},{"d":"2021-02-04","n":"Hansa Biopharma year-end report Jan-Dec 2020","u":"/media/press-releases/2021/hansa-biopharma-year-end-report-jan-dec-2020/"},{"d":"2021-01-27","n":"Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-2020-and-business-update/"},{"d":"2021-01-11","n":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference","u":"/media/press-releases/2021/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference/"},{"d":"2020-12-23","n":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference","u":"/media/press-releases/2020/hansa-biopharma-to-present-at-the-39th-annual-jp-morgan-healthcare-conference/"},{"d":"2020-11-02","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2020/hansa-biopharma-nomination-committee-formed/"},{"d":"2020-10-22","n":"Hansa Biopharma interim report Jan-Sep 2020","u":"/media/press-releases/2020/hansa-biopharma-interim-report-jan-sep-2020/"},{"d":"2020-09-24","n":"Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease","u":"/media/press-releases/2020/hansa-biopharm-announces-positive-high-level-data-from-investigator-initiated-phase-2-trial-with-imlifidase-to-treat-anti-gbm-disease/"},{"d":"2020-09-17","n":"Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen","u":"/media/press-releases/2020/hansa-biopharma-to-host-capital-markets-day-on-thursday-october-29-2020-in-copenhagen/"},{"d":"2020-09-11","n":"Hansa Biopharma AB certified as a Great Place to Work[® ]","u":"/media/press-releases/2020/hansa-biopharma-ab-certified-as-a-great-place-to-work-/"},{"d":"2020-09-01","n":"Hansa Biopharma provides updated guidance on its clinical programs","u":"/media/press-releases/2020/hansa-biopharma-provides-updated-guidance-on-its-clinical-programs/"},{"d":"2020-08-31","n":"Hansa Biopharma announces participation in Fall conferences and an updated financial calendar","u":"/media/press-releases/2020/hansa-biopharma-announces-participation-in-fall-conferences-and-an-updated-financial-calendar/"},{"d":"2020-08-26","n":"The EU Commission grants conditional approval for Idefirix[TM] (imlifidase) in highly sensitized kidney transplant patients in the European Union","u":"/media/press-releases/2020/the-eu-commission-grants-conditional-approval-for-idefirixtm-imlifidase-in-highly-sensitized-kidney-transplant-patients-in-the-european-union/"},{"d":"2020-07-31","n":"Hansa Biopharma announces increase in number of shares and votes","u":"/media/press-releases/2020/hansa-biopharma-announces-increase-in-number-of-shares-and-votes/"},{"d":"2020-07-16","n":"Hansa Biopharma expands the leadership team with the appointment of Katja Margell as new Head of Corporate Communications","u":"/media/press-releases/2020/hansa-biopharma-expands-the-leadership-team-with-the-appointment-of-katja-margell-as-new-head-of-corporate-communications/"},{"d":"2020-07-16","n":"Hansa Biopharma interim report Jan-Jun 2020","u":"/media/press-releases/2020/hansa-biopharma-interim-report-jan-jun-2020/"},{"d":"2020-07-08","n":"Hansa Biopharma announces successful completion of SEK 1.1bn (USD 121m) placing of newly issued shares","u":"/media/press-releases/2020/hansa-biopharma-announces-successful-completion-of-sek-11bn-usd-121m-placing-of-newly-issued-shares/"},{"d":"2020-07-08","n":"Hansa Biopharma announces intention to carry out a placing of new ordinary shares","u":"/media/press-releases/2020/hansa-biopharma-announces-intention-to-carry-out-a-placing-of-new-ordinary-shares/"},{"d":"2020-07-02","n":"Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications","u":"/media/press-releases/2020/hansa-biopharma-announces-exclusive-agreement-with-sarepta-therapeutics-to-develop-and-promote-imlifidase-as-pre-treatment-ahead-of-gene-therapy-in-select-indications/"},{"d":"2020-06-30","n":"Hansa Biopharma to host conference call to provide interim results for the first half of 2020 and business update","u":"/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-half-of-2020-and-business-update/"},{"d":"2020-06-25","n":"Hansa Biopharma receives positive CHMP opinion for Idefirix[TM] (imlifidase) for kidney transplant in EU","u":"/media/press-releases/2020/hansa-biopharma-receives-positive-chmp-opinion-for-idefirixtm-imlifidase-for-kidney-transplant-in-eu/"},{"d":"2020-06-23","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2020/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2020-05-29","n":"Hansa Biopharma appoints Achim Kaufhold as CMO to support the expansion outside transplantation","u":"/media/press-releases/2020/hansa-biopharma-appoints-achim-kaufhold-as-cmo-to-support-the-expansion-outside-transplantation/"},{"d":"2020-05-25","n":"Hansa Biopharma submits responses to outstanding questions from EMA on May 26. Review is on track; an opinion from CHMP is expected by end of June.","u":"/media/press-releases/2020/hansa-biopharma-submits-responses-to-outstanding-questions-from-ema-on-may-26-review-is-on-track-an-opinion-from-chmp-is-expected-by-end-of-june/"},{"d":"2020-05-20","n":"Hansa Biopharma announces upcoming presentations including a late breaking poster presentation at the 2020 American Transplant Congress","u":"/media/press-releases/2020/hansa-biopharma-announces-upcoming-presentations-including-a-late-breaking-poster-presentation-at-the-2020-american-transplant-congress/"},{"d":"2020-05-20","n":"Notice to Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2020/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2020-05-13","n":"Hansa Biopharma to participate in five upcoming investor conferences during May and June","u":"/media/press-releases/2020/hansa-biopharma-to-participate-in-five-upcoming-investor-conferences-during-may-and-june/"},{"d":"2020-04-28","n":"Hansa Biopharma interim report Jan-Mar 2020. EMA process on track; an opinion from the CHMP is expected in the second quarter 2020.","u":"/media/press-releases/2020/hansa-biopharma-interim-report-jan-mar-2020-ema-process-on-track-an-opinion-from-the-chmp-is-expected-in-the-second-quarter-2020/"},{"d":"2020-04-15","n":"Hansa Biopharma to host conference call to provide interim results for the first quarter of 2020 and business update","u":"/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-quarter-of-2020-and-business-update/"},{"d":"2020-04-02","n":"Hansa Biopharma publishes Annual Report 2019","u":"/media/press-releases/2020/hansa-biopharma-publishes-annual-report-2019/"},{"d":"2020-03-06","n":"Hansa Biopharma announces long term follow-up data that demonstrates 2-year graft survival of 89% after imlifdase treatment and transplantation","u":"/media/press-releases/2020/hansa-biopharma-announces-long-term-follow-up-data-that-demonstrates-2-year-graft-survival-of-89-after-imlifdase-treatment-and-transplantation/"},{"d":"2020-02-25","n":"Hansa Biopharma to participate in two upcoming investor conferences","u":"/media/press-releases/2020/hansa-biopharma-to-participate-in-two-upcoming-investor-conferences/"},{"d":"2020-02-06","n":"Hansa Biopharma Year-End Report 2019","u":"/media/press-releases/2020/hansa-biopharma-year-end-report-2019/"},{"d":"2020-01-27","n":"Hansa Biopharma completes enrollment in anti-GBM","u":"/media/press-releases/2020/hansa-biopharma-completes-enrollment-in-anti-gbm/"},{"d":"2020-01-22","n":"Hansa Biopharma to host conference call to provide Year-End report 2019 and Business Update","u":"/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-2019-and-business-update/"},{"d":"2020-01-12","n":"Hansa Biopharma provides business update ahead of the JP Morgan Global Healthcare Conference","u":"/media/press-releases/2020/hansa-biopharma-provides-business-update-ahead-of-the-jp-morgan-global-healthcare-conference/"},{"d":"2019-12-13","n":"Hansa Biopharma has agreed with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S.","u":"/media/press-releases/2019/hansa-biopharma-has-agreed-with-the-fda-on-a-regulatory-path-forward-for-imlifidase-in-kidney-transplantation-of-highly-sensitized-patients-in-the-us/"},{"d":"2019-11-19","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2019/hansa-biopharma-nomination-committee-formed/"},{"d":"2019-10-31","n":"Hansa Biopharma Interim Report January–September 2019","u":"/media/press-releases/2019/hansa-biopharma-interim-report-januaryseptember-2019/"},{"d":"2019-10-11","n":"Hansa Biopharma to host conference call to provide interim results for the first nine months of 2019 and business update","u":"/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-nine-months-of-2019-and-business-update/"},{"d":"2019-09-30","n":"Increase of number of shares and votes in Hansa Biopharma AB","u":"/media/press-releases/2019/increase-of-number-of-shares-and-votes-in-hansa-biopharma-ab/"},{"d":"2019-09-25","n":"Hansa Biopharma confirms follow-up meeting with FDA","u":"/media/press-releases/2019/hansa-biopharma-confirms-follow-up-meeting-with-fda/"},{"d":"2019-09-18","n":"Hansa Biopharma: Positive results presented at ESOT; imlifidase enabled  transplantation in 46 sensitized patients","u":"/media/press-releases/2019/hansa-biopharma-positive-results-presented-at-esot-imlifidase-enabled--transplantation-in-46-sensitized-patients/"},{"d":"2019-09-02","n":"Hansa Biopharma: Issue and re-purchase of class C shares for incentive programme","u":"/media/press-releases/2019/hansa-biopharma-issue-and-re-purchase-of-class-c-shares-for-incentive-programme/"},{"d":"2019-08-30","n":"Hansa Biopharma: New imlifidase data presented at ESOT, Copenhagen","u":"/media/press-releases/2019/hansa-biopharma-new-imlifidase-data-presented-at-esot-copenhagen/"},{"d":"2019-08-21","n":"Hansa Biopharma to participate in three upcoming investor conferences","u":"/media/press-releases/2019/hansa-biopharma-to-participate-in-three-upcoming-investor-conferences/"},{"d":"2019-07-18","n":"Hansa Biopharma Interim Report January–June 2019","u":"/media/press-releases/2019/hansa-biopharma-interim-report-januaryjune-2019/"},{"d":"2019-07-05","n":"Hansa Biopharma to Host Conference Call to Provide Second Quarter 2019 Business Update","u":"/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-second-quarter-2019-business-update/"},{"d":"2019-06-07","n":"Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls","u":"/media/press-releases/2019/plenary-presentation-at-the-2019-american-transplant-congress-demonstrates-significant-reduction-in-time-on-the-waitlist-for-patients-treated-with-imlifidase-compared-to-matched-controls/"},{"d":"2019-05-22","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2019/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2019-05-13","n":"Hansa Biopharma to participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City","u":"/media/press-releases/2019/hansa-biopharma-to-participate-in-ubs-global-healthcare-conference-and-rbc-capital-markets-global-healthcare-conference-in-new-york-city/"},{"d":"2019-05-02","n":"Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress","u":"/media/press-releases/2019/hansa-biopharma-announces-upcoming-presentations-at-the-2019-american-transplant-congress/"},{"d":"2019-04-29","n":"Hansa Biopharma expands leadership team with dedicated roles for Corporate Communications, Investor Relations and Business Development","u":"/media/press-releases/2019/hansa-biopharma-expands-leadership-team-with-dedicated-roles-for-corporate-communications-investor-relations-and-business-development/"},{"d":"2019-04-29","n":"Hansa Biopharma Interim Report January–March 2019","u":"/media/press-releases/2019/hansa-biopharma-interim-report-januarymarch-2019/"},{"d":"2019-04-23","n":"Hansa Biopharma to Host Conference Call to Provide First Quarter 2019 Business Update","u":"/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-first-quarter-2019-business-update/"},{"d":"2019-04-17","n":"Notice to Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2019/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2019-04-15","n":"Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome","u":"/media/press-releases/2019/hansa-biopharma-receives-ethics-and-regulatory-clearance-to-start-phase-2-study-of-imlifidase-in-guillain-barre-syndrome/"},{"d":"2019-04-15","n":"Hansa Biopharma divests its equity holding in Genovis","u":"/media/press-releases/2019/hansa-biopharma-divests-its-equity-holding-in-genovis/"},{"d":"2019-04-15","n":"Hansa Biopharma publishes the Annual Report for 2018","u":"/media/press-releases/2019/hansa-biopharma-publishes-the-annual-report-for-2018/"},{"d":"2019-03-26","n":"Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation","u":"/media/press-releases/2019/hansa-biopharma-receives-ethics-and-regulatory-clearance-to-start-phase-2-study-of-imlifidase-in-acute-antibody-mediated-rejection-in-kidney-transplantation/"},{"d":"2019-03-21","n":"Hansa Biopharma Announces Selection of NiceR Lead Candidate","u":"/media/press-releases/2019/hansa-biopharma-announces-selection-of-nicer-lead-candidate/"},{"d":"2019-03-06","n":"Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference","u":"/media/press-releases/2019/hansa-biopharma-to-present-at-the-cowen-39th-annual-health-care-conference/"},{"d":"2019-03-01","n":"Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX™ (imlifidase)","u":"/media/press-releases/2019/hansa-biopharma-announces-european-medicines-agency-accepts-marketing-authorization-application-for-idefirix-imlifidase/"},{"d":"2019-02-28","n":"Increase of number of shares and votes in Hansa Biopharma AB (publ)","u":"/media/press-releases/2019/increase-of-number-of-shares-and-votes-in-hansa-biopharma-ab-publ/"},{"d":"2019-02-08","n":"Hansa Biopharma Year-End Report 2018","u":"/media/press-releases/2019/hansa-biopharma-year-end-report-2018/"},{"d":"2019-02-07","n":"Hansa Biopharma appoints Donato Spota as new Chief Financial Officer","u":"/media/press-releases/2019/hansa-biopharma-appoints-donato-spota-as-new-chief-financial-officer/"},{"d":"2019-01-31","n":"Hansa Medical to Host Conference Call to Provide Year-End Report 2018 Business Update","u":"/media/press-releases/2019/hansa-medical-to-host-conference-call-to-provide-year-end-report-2018-business-update/"},{"d":"2019-01-31","n":"Increase of number of votes in Hansa Medical AB (publ)","u":"/media/press-releases/2019/increase-of-number-of-votes-in-hansa-medical-ab-publ/"},{"d":"2019-01-18","n":"Hansa Medical Announces Appointment of Anne Säfström Lanner as Vice President, Global Human Resources","u":"/media/press-releases/2019/hansa-medical-announces-appointment-of-anne-safstrom-lanner-as-vice-president-global-human-resources/"},{"d":"2019-01-15","n":"Hansa Medical AB Provides Regulatory Update for Imlifidase in Kidney Transplantation","u":"/media/press-releases/2019/hansa-medical-ab-provides-regulatory-update-for-imlifidase-in-kidney-transplantation/"},{"d":"2018-12-20","n":"Hansa Medical AB to change name to Hansa Biopharma AB","u":"/media/press-releases/2018/hansa-medical-ab-to-change-name-to-hansa-biopharma-ab/"},{"d":"2018-12-11","n":"Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2018/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2018-11-30","n":"Hansa Medical AB Announces Increase in Number of Shares and Votes","u":"/media/press-releases/2018/hansa-medical-ab-announces-increase-in-number-of-shares-and-votes/"},{"d":"2018-11-21","n":"Hansa Medical AB to Present at the Evercore ISI HealthConX Conference","u":"/media/press-releases/2018/hansa-medical-ab-to-present-at-the-evercore-isi-healthconx-conference/"},{"d":"2018-11-09","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2018/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2018-11-01","n":"Hansa Medical Interim report July – September 2018","u":"/media/press-releases/2018/hansa-medical-interim-report-july--september-2018/"},{"d":"2018-10-31","n":"Increase of Number of Shares and Votes in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ/"},{"d":"2018-10-29","n":"Bulletin from the Extraordinary General Meeting of Hansa Medical AB","u":"/media/press-releases/2018/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab/"},{"d":"2018-10-26","n":"Presentation at ASN Kidney Week 2018 Highlights Stable Renal Function at up to 24 Months Following Transplantation Enabled by Imlifidase","u":"/media/press-releases/2018/presentation-at-asn-kidney-week-2018-highlights-stable-renal-function-at-up-to-24-months-following-transplantation-enabled-by-imlifidase/"},{"d":"2018-10-25","n":"Hansa Medical's Nomination Committee for the AGM 2019 Appointed and 2019 Financial Calendar Published","u":"/media/press-releases/2018/hansa-medicals-nomination-committee-for-the-agm-2019-appointed-and-2019-financial-calendar-published/"},{"d":"2018-10-25","n":"Hansa Medical to Report Interim Results for the Third Quarter of 2018 and Host Conference Call and Webcast","u":"/media/press-releases/2018/hansa-medical-to-report-interim-results-for-the-third-quarter-of-2018-and-host-conference-call-and-webcast/"},{"d":"2018-10-24","n":"Hansa Medical Receives Positive Opinion for Orphan Drug Designation in the EU for Imlifidase for Anti-GBM Disease","u":"/media/press-releases/2018/hansa-medical-receives-positive-opinion-for-orphan-drug-designation-in-the-eu-for-imlifidase-for-anti-gbm-disease/"},{"d":"2018-10-17","n":"Hansa Medical Receives FDA Fast Track Designation for Imlifidase for Transplantation","u":"/media/press-releases/2018/hansa-medical-receives-fda-fast-track-designation-for-imlifidase-for-transplantation/"},{"d":"2018-10-05","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2018/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ-2018-10-05/"},{"d":"2018-09-27","n":"Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation","u":"/media/press-releases/2018/hansa-medical-reports-positive-final-top-line-results-from-two-phase-2-studies-of-imlifidase-for-kidney-transplantation/"},{"d":"2018-09-17","n":"Hansa Medical Announces Appointment of Vincenza Nigro as Vice President, Global Medical Affairs","u":"/media/press-releases/2018/hansa-medical-announces-appointment-of-vincenza-nigro-as-vice-president-global-medical-affairs/"},{"d":"2018-09-06","n":"Issue and repurchase of class C shares for incentive program","u":"/media/press-releases/2018/issue-and-repurchase-of-class-c-shares-for-incentive-program/"},{"d":"2018-08-06","n":"Hansa Medical initiates follow up study of patients treated with lead candidate imlifidase (IdeS) prior to kidney transplantation","u":"/media/press-releases/2018/hansa-medical-initiates-follow-up-study-of-patients-treated-with-lead-candidate-imlifidase-ides-prior-to-kidney-transplantation/"},{"d":"2018-07-31","n":"Increase of number of shares and votes in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ-2018-07-31/"},{"d":"2018-07-19","n":"Hansa Medical Interim report April – June 2018","u":"/media/press-releases/2018/hansa-medical-interim-report-april--june-2018/"},{"d":"2018-07-12","n":"Hansa Medical to Host Conference Call to Provide Second Quarter 2018 Business Update","u":"/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-second-quarter-2018-business-update/"},{"d":"2018-07-09","n":"Hansa Medical lead candidate imlifidase (IdeS) granted orphan drug designation by the FDA for anti-GBM antibody disease","u":"/media/press-releases/2018/hansa-medical-lead-candidate-imlifidase-ides-granted-orphan-drug-designation-by-the-fda-for-anti-gbm-antibody-disease/"},{"d":"2018-06-29","n":"Increase of number of shares in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-shares-in-hansa-medical-ab-publ/"},{"d":"2018-06-15","n":"Hansa Medical’s warrant program TO2015 has opened for exercise and subscription of shares","u":"/media/press-releases/2018/hansa-medicals-warrant-program-to2015-has-opened-for-exercise-and-subscription-of-shares/"},{"d":"2018-06-06","n":"Presentation at the 2018 American Transplant Congress highlights the long-term risk-benefit profile of imlifidase (IdeS) in kidney transplantation","u":"/media/press-releases/2018/presentation-at-the-2018-american-transplant-congress-highlights-the-long-term-risk-benefit-profile-of-imlifidase-ides-in-kidney-transplantation/"},{"d":"2018-05-30","n":"Long-term follow up data from investigator-initiated Phase II study with imlifidase (IdeS) to be presented at 2018 American Transplant Congress (ATC)","u":"/media/press-releases/2018/long-term-follow-up-data-from-investigator-initiated-phase-ii-study-with-imlifidase-ides-to-be-presented-at-2018-american-transplant-congress-atc/"},{"d":"2018-05-29","n":"Bulletin from the Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2018/bulletin-from-the-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2018-04-25","n":"Hansa Medical Interim Report January–March 2018","u":"/media/press-releases/2018/hansa-medical-interim-report-januarymarch-2018/"},{"d":"2018-04-25","n":"Notice to Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2018/notice-to-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2018-04-18","n":"Hansa Medical to Host Conference Call to Provide First Quarter 2018 Business Update","u":"/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-first-quarter-2018-business-update/"},{"d":"2018-04-11","n":"Hansa Medical publishes the Annual Report for 2017","u":"/media/press-releases/2018/hansa-medical-publishes-the-annual-report-for-2017/"},{"d":"2018-03-21","n":"The American Journal of Transplantation publishes results from Hansa Medical's first Phase II study with IdeS","u":"/media/press-releases/2018/the-american-journal-of-transplantation-publishes-results-from-hansa-medicals-first-phase-ii-study-with-ides/"},{"d":"2018-03-20","n":"S��ren Tulstrup appointed new President and CEO of Hansa Medical","u":"/media/press-releases/2018/soren-tulstrup-appointed-new-president-and-ceo-of-hansa-medical/"},{"d":"2018-02-16","n":"Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barré syndrome","u":"/media/press-releases/2018/hansa-medical-receives-fda-orphan-drug-designation-for-ides-and-the-treatment-of-guillain-barre-syndrome/"},{"d":"2018-02-14","n":"Intermediate evaluation of a sub-population in the Highdes study demonstrates good kidney function 5.5 months (median) post transplantation","u":"/media/press-releases/2018/intermediate-evaluation-of-a-sub-population-in-the-highdes-study-demonstrates-good-kidney-function-55-months-median-post-transplantation/"},{"d":"2018-02-14","n":"Hansa Medical Year-End Report 2017","u":"/media/press-releases/2018/hansa-medical-year-end-report-2017/"},{"d":"2018-02-07","n":"Hansa Medical to Host Conference Call to Provide Year-End Report 2017 Business Update","u":"/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-year-end-report-2017-business-update/"},{"d":"2018-01-31","n":"Increase of number of votes in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-votes-in-hansa-medical-ab-publ/"},{"d":"2018-01-04","n":"Completed enrollment in Hansa Medical’s international multi-center Phase II study Highdes","u":"/media/press-releases/2018/completed-enrollment-in-hansa-medicals-international-multi-center-phase-ii-study-highdes/"},{"d":"2018-01-03","n":"Finalized enrollment in US Phase II study with IdeS in highly sensitized patients","u":"/media/press-releases/2018/finalized-enrollment-in-us-phase-ii-study-with-ides-in-highly-sensitized-patients/"},{"d":"2017-12-29","n":"Increase of number of shares and votes in Hansa Medical AB (publ)","u":"/media/press-releases/2017/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ/"},{"d":"2017-12-22","n":"Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2017/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2017-11-30","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2017/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2017-11-17","n":"Hansa Medical's Nomination Committee for the AGM 2018 appointed","u":"/media/press-releases/2017/hansa-medicals-nomination-committee-for-the-agm-2018-appointed/"},{"d":"2017-11-14","n":"Hansa Medical Interim report July – September 2017","u":"/media/press-releases/2017/hansa-medical-interim-report-july--september-2017/"},{"d":"2017-11-09","n":"The time point for Hansa Medical’s Third Quarter 2017 Business Update Conference Call has been changed","u":"/media/press-releases/2017/the-time-point-for-hansa-medicals-third-quarter-2017-business-update-conference-call-has-been-changed/"},{"d":"2017-11-08","n":"Hansa Medical announces sudden death of CEO Göran Arvidson","u":"/media/press-releases/2017/hansa-medical-announces-sudden-death-of-ceo-goran-arvidson/"},{"d":"2017-11-07","n":"Hansa Medical to Host Conference Call to Provide Third Quarter 2017 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-third-quarter-2017-business-update/"},{"d":"2017-10-03","n":"Hansa Medical’s Capital Market Days provide an update on number of patients included in the company’s kidney transplantation and anti-GBM studies","u":"/media/press-releases/2017/hansa-medicals-capital-market-days-provide-an-update-on-number-of-patients-included-in-the-companys-kidney-transplantation-and-anti-gbm-studies/"},{"d":"2017-10-03","n":"Hansa Medical’s Capital Market Days provide an update on number of patients included in the company’s kidney transplantation and anti-GBM studies","u":"/media/press-releases/2017/hansa-medicals-capital-market-days-provide-an-update-on-number-of-patients-included-in-the-companys-kidney-transplantation-and-anti-gbm-studies-2017-10-03/"},{"d":"2017-09-22","n":"Hansa Medical announces agenda for Capital Markets Days in Stockholm & London","u":"/media/press-releases/2017/hansa-medical-announces-agenda-for-capital-markets-days-in-stockholm--london/"},{"d":"2017-08-23","n":"SAVE THE DATE: Tuesday 3 & Wednesday 4 October 2017, Hansa Medical’s Capital Markets Days, Stockholm & London","u":"/media/press-releases/2017/save-the-date-tuesday-3--wednesday-4-october-2017-hansa-medicals-capital-markets-days-stockholm--london/"},{"d":"2017-08-02","n":"The New England Journal of Medicine publishes results from Phase II studies of Hansa Medical’s lead candidate IdeS in highly sensitized patients","u":"/media/press-releases/2017/the-new-england-journal-of-medicine-publishes-results-from-phase-ii-studies-of-hansa-medicals-lead-candidate-ides-in-highly-sensitized-patients/"},{"d":"2017-07-20","n":"Hansa Medical Interim report April-June 2017","u":"/media/press-releases/2017/hansa-medical-interim-report-april-june-2017/"},{"d":"2017-07-13","n":"Hansa Medical to Host Conference Call to Provide Second Quarter 2017 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-second-quarter-2017-business-update/"},{"d":"2017-06-20","n":"First patient treated in Phase II study with IdeS in anti-GBM antibody disease","u":"/media/press-releases/2017/first-patient-treated-in-phase-ii-study-with-ides-in-anti-gbm-antibody-disease/"},{"d":"2017-06-07","n":"Hansa Medical to present at Jefferies 2017 Global Healthcare Conference","u":"/media/press-releases/2017/hansa-medical-to-present-at-jefferies-2017-global-healthcare-conference/"},{"d":"2017-05-31","n":"Increase of number of shares and votes in Hansa Medical AB (publ)","u":"/media/press-releases/2017/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ-2017-05-31/"},{"d":"2017-05-24","n":"Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2017/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2017-05-23","n":"Published preclinical results confirm IdeS potential in cancer immunotherapy","u":"/media/press-releases/2017/published-preclinical-results-confirm-ides-potential-in-cancer-immunotherapy/"},{"d":"2017-05-19","n":"IdeS selected for EMA Priority Medicines (PRIME) scheme","u":"/media/press-releases/2017/ides-selected-for-ema-priority-medicines-prime-scheme/"},{"d":"2017-05-12","n":"Lead candidate IdeS discussed in FDA workshop","u":"/media/press-releases/2017/lead-candidate-ides-discussed-in-fda-workshop/"},{"d":"2017-04-27","n":"Issue and repurchase of class C shares for incentive program","u":"/media/press-releases/2017/issue-and-repurchase-of-class-c-shares-for-incentive-program/"},{"d":"2017-04-26","n":"Interim report January – March 2017","u":"/media/press-releases/2017/interim-report-january--march-2017/"},{"d":"2017-04-26","n":"Hansa Medical publishes the Annual Report for 2016","u":"/media/press-releases/2017/hansa-medical-publishes-the-annual-report-for-2016/"},{"d":"2017-04-24","n":"NOTICE OF ANNUAL GENERAL MEETING IN Hansa Medical AB (publ)","u":"/media/press-releases/2017/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2017-04-19","n":"Hansa Medical to Host Conference Call to Provide First Quarter 2017 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-first-quarter-2017-business-update/"},{"d":"2017-03-31","n":"Hansa Medical appoints Sam Agus as new Chief Medical Officer","u":"/media/press-releases/2017/hansa-medical-appoints-sam-agus-as-new-chief-medical-officer/"},{"d":"2017-03-29","n":"Top-line clinical results from US study with lead candidate IdeS to be presented at the American Transplant Congress","u":"/media/press-releases/2017/top-line-clinical-results-from-us-study-with-lead-candidate-ides-to-be-presented-at-the-american-transplant-congress/"},{"d":"2017-03-08","n":"Hansa Medical to present at The Oppenheimer 27th Annual Healthcare Conference","u":"/media/press-releases/2017/hansa-medical-to-present-at-the-oppenheimer-27th-annual-healthcare-conference/"},{"d":"2017-02-16","n":"Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barré syndrome (GBS)","u":"/media/press-releases/2017/novel-pre-clinical-in-vivo-data-demonstrate-the-treatment-potential-of-ides-in-guillain-barre-syndrome-gbs/"},{"d":"2017-02-15","n":"Hansa Medical Year-End Report 2016","u":"/media/press-releases/2017/hansa-medical-year-end-report-2016/"},{"d":"2017-02-09","n":"Hansa Medical to Host Conference Call to Provide Fourth Quarter and Full Year 2016 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-fourth-quarter-and-full-year-2016-business-update/"},{"d":"2016-12-21","n":"Hansa Medical announces successful completion of a Phase II clinical trial of IdeS in sensitized kidney patients","u":"/media/press-releases/2016/hansa-medical-announces-successful-completion-of-a-phase-ii-clinical-trial-of-ides-in-sensitized-kidney-patients/"},{"d":"2016-12-21","n":"Hansa Medical discontinues its Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)","u":"/media/press-releases/2016/hansa-medical-discontinues-its-phase-ii-study-in-acquired-thrombotic-thrombocytopenic-purpura-ttp/"},{"d":"2016-12-15","n":"Hansa Medical’s application for Orphan Drug Designation for IdeS in the EU receives positive opinion","u":"/media/press-releases/2016/hansa-medicals-application-for-orphan-drug-designation-for-ides-in-the-eu-receives-positive-opinion/"},{"d":"2016-11-30","n":"Increase of number of shares in Hansa Medical AB (publ)","u":"/media/press-releases/2016/increase-of-number-of-shares-in-hansa-medical-ab-publ/"},{"d":"2016-11-21","n":"Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-11-09","n":"Hansa Medical Interim report July – September 2016","u":"/media/press-releases/2016/hansa-medical-interim-report-july--september-2016/"},{"d":"2016-11-09","n":"Hansa Medical's Nomination Committee for the AGM 2017 appointed","u":"/media/press-releases/2016/hansa-medicals-nomination-committee-for-the-agm-2017-appointed/"},{"d":"2016-10-20","n":"Hansa Medical proposes a directed share issue","u":"/media/press-releases/2016/hansa-medical-proposes-a-directed-share-issue/"},{"d":"2016-10-20","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-10-11","n":"First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)","u":"/media/press-releases/2016/first-patient-treated-with-ides-in-phase-ii-study-in-acquired-thrombotic-thrombocytopenic-purpura-ttp/"},{"d":"2016-10-03","n":"First patient treated in Hansa Medical’s Highdes-study","u":"/media/press-releases/2016/first-patient-treated-in-hansa-medicals-highdes-study/"},{"d":"2016-08-23","n":"Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented","u":"/media/press-releases/2016/top-line-results-from-the-swedish-ongoing-phase-ii-study-with-ides-in-sensitized-patients-presented/"},{"d":"2016-07-21","n":"Hansa Medical Interim report April – June 2016","u":"/media/press-releases/2016/hansa-medical-interim-report-april--june-2016/"},{"d":"2016-07-19","n":"Hansa Medical acquires rights to cancer immunotherapy using antibody-modulating enzymes","u":"/media/press-releases/2016/hansa-medical-acquires-rights-to-cancer-immunotherapy-using-antibody-modulating-enzymes/"},{"d":"2016-07-19","n":"Hansa Medical initiates pivotal multicenter study in the US with IdeS for treatment of refractory highly sensitized kidney patients","u":"/media/press-releases/2016/hansa-medical-initiates-pivotal-multicenter-study-in-the-us-with-ides-for-treatment-of-refractory-highly-sensitized-kidney-patients/"},{"d":"2016-06-30","n":"Genovis AB enters settlement and license agreement with Promega Corporation in patent infringement case","u":"/media/press-releases/2016/genovis-ab-enters-settlement-and-license-agreement-with-promega-corporation-in-patent-infringement-case/"},{"d":"2016-06-15","n":"Successful desensitization with IdeS in all recruited patients in ongoing US Phase II study","u":"/media/press-releases/2016/successful-desensitization-with-ides-in-all-recruited-patients-in-ongoing-us-phase-ii-study/"},{"d":"2016-05-31","n":"Initial results from the ongoing Swedish Phase II study with IdeS in sensitized kidney transplant patients will be presented at TTS 2016","u":"/media/press-releases/2016/initial-results-from-the-ongoing-swedish-phase-ii-study-with-ides-in-sensitized-kidney-transplant-patients-will-be-presented-at-tts-2016/"},{"d":"2016-05-17","n":"Ongoing US study shows that IdeS allows for transplantation of highly sensitized patients","u":"/media/press-releases/2016/ongoing-us-study-shows-that-ides-allows-for-transplantation-of-highly-sensitized-patients/"},{"d":"2016-05-12","n":"Hansa Medical appoints Henk Doude van Troostwijk as Vice President, Commercial Operations","u":"/media/press-releases/2016/hansa-medical-appoints-henk-doude-van-troostwijk-as-vice-president-commercial-operations/"},{"d":"2016-05-12","n":"Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-04-27","n":"Hansa Medical interim report January – March 2016","u":"/media/press-releases/2016/hansa-medical-interim-report-january--march-2016/"},{"d":"2016-04-19","n":"Patient recruitment completed in Phase II clinical study with IdeS in kidney transplantation","u":"/media/press-releases/2016/patient-recruitment-completed-in-phase-ii-clinical-study-with-ides-in-kidney-transplantation/"},{"d":"2016-04-12","n":"Notice of Annual General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/notice-of-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-04-06","n":"Proposed chairman Ulf Wiinberg buys shares in Hansa Medical","u":"/media/press-releases/2016/proposed-chairman-ulf-wiinberg-buys-shares-in-hansa-medical/"},{"d":"2016-04-04","n":"Ulf Wiinberg proposed as new chairman and Angelica Loskog new board member","u":"/media/press-releases/2016/ulf-wiinberg-proposed-as-new-chairman-and-angelica-loskog-new-board-member/"},{"d":"2016-04-04","n":"FDA clears Hansa Medical’s IND application for IdeS in kidney transplantation","u":"/media/press-releases/2016/fda-clears-hansa-medicals-ind-application-for-ides-in-kidney-transplantation/"},{"d":"2016-03-31","n":"Hansa Medical publishes the Annual Report for 2015","u":"/media/press-releases/2016/hansa-medical-publishes-the-annual-report-for-2015/"},{"d":"2016-03-24","n":"Hansa Medical postpones Annual General Meeting","u":"/media/press-releases/2016/hansa-medical-postpones-annual-general-meeting/"},{"d":"2016-03-11","n":"Study results presented in New England Journal of Medicine strengthen Hansa Medical's belief in the potential of IdeS","u":"/media/press-releases/2016/study-results-presented-in-new-england-journal-of-medicine-strengthen-hansa-medicals-belief-in-the-potential-of-ides/"},{"d":"2016-03-08","n":"Farstorps Gård AB has divested Hansa Medical shares","u":"/media/press-releases/2016/farstorps-gard-ab-has-divested-hansa-medical-shares/"},{"d":"2016-02-18","n":"Hansa Medical AB (publ) - Year-End Report 2015","u":"/media/press-releases/2016/hansa-medical-ab-publ---year-end-report-2015/"},{"d":"2015-12-08","n":"Swedish and international investors acquire 2 million shares in Hansa Medical AB from Farstorps Gård AB","u":"/media/press-releases/2015/swedish-and-international-investors-acquire-2-million-shares-in-hansa-medical-ab-from-farstorps-gard-ab/"},{"d":"2015-11-13","n":"Well attended Capital Markets Day by Hansa Medical","u":"/media/press-releases/2015/well-attended-capital-markets-day-by-hansa-medical/"},{"d":"2015-11-13","n":"Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies","u":"/media/press-releases/2015/data-shows-that-one-dose-of-ides-has-favorable-effect-and-completely-removes-hla-antibodies/"},{"d":"2015-11-10","n":"Data showing that IdeS can silence memory B-cells published in Journal of Immunology","u":"/media/press-releases/2015/data-showing-that-ides-can-silence-memory-b-cells-published-in-journal-of-immunology/"},{"d":"2015-11-02","n":"Trading of Hansa Medical's share initiated on Nasdaq Stockholm main market","u":"/media/press-releases/2015/trading-of-hansa-medicals-share-initiated-on-nasdaq-stockholm-main-market/"},{"d":"2015-10-28","n":"Hansa Medical interim report January – September 2015","u":"/media/press-releases/2015/hansa-medical-interim-report-january--september-2015/"},{"d":"2015-10-27","n":"Hansa Medical’s Nomination Committee appointed","u":"/media/press-releases/2015/hansa-medicals-nomination-committee-appointed/"},{"d":"2015-10-27","n":"Hansa Medical announces prospectus","u":"/media/press-releases/2015/hansa-medical-announces-prospectus/"},{"d":"2015-10-22","n":"Hansa Medical’s shares admitted to trading on Nasdaq Stockholm","u":"/media/press-releases/2015/hansa-medicals-shares-admitted-to-trading-on-nasdaq-stockholm/"},{"d":"2015-10-13","n":"Hansa Medical applies for stock exchange listing","u":"/media/press-releases/2015/hansa-medical-applies-for-stock-exchange-listing/"},{"d":"2015-10-06","n":"Hansa Medical invites to a Capital Markets Day in Stockholm, November the 13th 2015","u":"/media/press-releases/2015/hansa-medical-invites-to-a-capital-markets-day-in-stockholm-november-the-13th-2015/"},{"d":"2015-09-15","n":"Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015","u":"/media/press-releases/2015/data-from-hansa-medicals-first-phase-ii-study-of-ides-in-sensitized-kidney-transplantation-patients-presented-in-oral-session-at-esot-2015/"},{"d":"2015-09-14","n":"Hansa Medical receives FDA Orphan Drug Designation for IdeS","u":"/media/press-releases/2015/hansa-medical-receives-fda-orphan-drug-designation-for-ides/"},{"d":"2015-08-27","n":"Results from a clinical multicenter trial with HBP-assay published in Critical Care Medicine","u":"/media/press-releases/2015/results-from-a-clinical-multicenter-trial-with-hbp-assay-published-in-critical-care-medicine/"},{"d":"2015-08-25","n":"Hansa Medical Interim report January – June 2015","u":"/media/press-releases/2015/hansa-medical-interim-report-january--june-2015/"},{"d":"2015-08-11","n":"First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation","u":"/media/press-releases/2015/first-patient-in-ides-study-at-cedars-sinai-medical-center-in-los-angeles-receives-kidney-transplantation/"},{"d":"2015-07-16","n":"Positive IdeS phase I data published in scientific journal PLOS ONE","u":"/media/press-releases/2015/positive-ides-phase-i-data-published-in-scientific-journal-plos-one/"},{"d":"2015-06-15","n":"First patient in IdeS phase II study transplanted","u":"/media/press-releases/2015/first-patient-in-ides-phase-ii-study-transplanted/"},{"d":"2015-06-10","n":"Board members, management and employees acquire Hansa Medical shares and warrants","u":"/media/press-releases/2015/board-members-management-and-employees-acquire-hansa-medical-shares-and-warrants/"},{"d":"2015-06-03","n":"Hans Schikan elected as new Board member in Hansa Medical AB (publ)","u":"/media/press-releases/2015/hans-schikan-elected-as-new-board-member-in-hansa-medical-ab-publ/"},{"d":"2015-06-03","n":"Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2015/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2015-05-06","n":"Hansa Medical AB establishes a US medical advisory board for IdeS in kidney transplantation","u":"/media/press-releases/2015/hansa-medical-ab-establishes-a-us-medical-advisory-board-for-ides-in-kidney-transplantation/"},{"d":"2015-05-04","n":"Notice of Annual General Meeting of Hansa Medical; Hans Schikan nominated to the Board of Directors","u":"/media/press-releases/2015/notice-of-annual-general-meeting-of-hansa-medical-hans-schikan-nominated-to-the-board-of-directors/"},{"d":"2015-04-30","n":"Professor Stanley Jordan, a leading expert in transplant immunology, initiates IdeS-study in USA","u":"/media/press-releases/2015/professor-stanley-jordan-a-leading-expert-in-transplant-immunology-initiates-ides-study-in-usa/"},{"d":"2015-04-30","n":"Göran Arvidson new President and CEO of Hansa Medical","u":"/media/press-releases/2015/goran-arvidson-new-president-and-ceo-of-hansa-medical/"},{"d":"2015-04-29","n":"Hansa Medical publishes the Annual Report for 2014","u":"/media/press-releases/2015/hansa-medical-publishes-the-annual-report-for-2014/"},{"d":"2015-04-16","n":"Hansa Medical Interim report January – March 2015","u":"/media/press-releases/2015/hansa-medical-interim-report-january--march-2015/"},{"d":"2015-04-09","n":"Hansa Medical’s SEK 246 million rights issue fully subscribed","u":"/media/press-releases/2015/hansa-medicals-sek-246-million-rights-issue-fully-subscribed/"},{"d":"2015-03-20","n":"Hansa Medical postpones the publishing of the annual report for the financial year of 2014","u":"/media/press-releases/2015/hansa-medical-postpones-the-publishing-of-the-annual-report-for-the-financial-year-of-2014/"},{"d":"2015-03-18","n":"Hansa Medical announces prospectus","u":"/media/press-releases/2015/hansa-medical-announces-prospectus-2015-03-18/"},{"d":"2015-03-16","n":"Hansa Medical postpones annual general meeting","u":"/media/press-releases/2015/hansa-medical-postpones-annual-general-meeting/"},{"d":"2015-03-02","n":"Hansa Medical’s CFO appointed acting CEO","u":"/media/press-releases/2015/hansa-medicals-cfo-appointed-acting-ceo/"},{"d":"2015-02-23","n":"Change of ownership in Hansa Medical","u":"/media/press-releases/2015/change-of-ownership-in-hansa-medical/"},{"d":"2015-02-23","n":"Hansa Medical announces fully underwritten SEK 246 million rights issue","u":"/media/press-releases/2015/hansa-medical-announces-fully-underwritten-sek-246-million-rights-issue/"},{"d":"2015-02-19","n":"Hansa Medical appoints members of committees – Lars Björck and Hans Wigzell external members of scientific committee","u":"/media/press-releases/2015/hansa-medical-appoints-members-of-committees--lars-bjorck-and-hans-wigzell-external-members-of-scientific-committee/"},{"d":"2015-02-18","n":"Hansa Medical licensee Axis-Shield Diagnostic Limited enters agreement with Hangzhou Joinstar Biomedical Technology Co Ltd","u":"/media/press-releases/2015/hansa-medical-licensee-axis-shield-diagnostic-limited-enters-agreement-with-hangzhou-joinstar-biomedical-technology-co-ltd/"},{"d":"2015-02-18","n":"Comments to CEO presentation at Redeye on 17 February 2015 at 18.30","u":"/media/press-releases/2015/comments-to-ceo-presentation-at-redeye-on-17-february-2015-at-1830/"},{"d":"2015-02-16","n":"Hansa Medical AB has engaged Carnegie Investment Bank AB as financial advisor","u":"/media/press-releases/2015/hansa-medical-ab-has-engaged-carnegie-investment-bank-ab-as-financial-advisor/"},{"d":"2015-02-13","n":"Hansa Medical Year-End Report 2014","u":"/media/press-releases/2015/hansa-medical-year-end-report-2014/"},{"d":"2015-02-12","n":"Hansa Medical AB applies for listing on Nasdaq Stockholm","u":"/media/press-releases/2015/hansa-medical-ab-applies-for-listing-on-nasdaq-stockholm/"},{"d":"2015-02-12","n":"Hansa Medical develops second-generation IdeS molecules for repeat dosing","u":"/media/press-releases/2015/hansa-medical-develops-second-generation-ides-molecules-for-repeat-dosing/"},{"d":"2015-02-05","n":"Hansa Medical AB announces cooperation with Cedars-Sinai Medical Center’s Comprehensive Transplant Center and US transplantation expert Stanley Jordan","u":"/media/press-releases/2015/hansa-medical-ab-announces-cooperation-with-cedars-sinai-medical-centers-comprehensive-transplant-center-and-us-transplantation-expert-stanley-jordan/"},{"d":"2015-02-03","n":"Hansa Medical nomination committee for the Annual General Meeting 2015 has been established","u":"/media/press-releases/2015/hansa-medical-nomination-committee-for-the-annual-general-meeting-2015-has-been-established/"},{"d":"2015-02-02","n":"Hansa Medical AB takes up a 20 MSEK loan from principal shareholder Nexttobe AB","u":"/media/press-releases/2015/hansa-medical-ab-takes-up-a-20-msek-loan-from-principal-shareholder-nexttobe-ab/"},{"d":"2015-01-29","n":"Hansa Medical AB announces the formation of a medical advisory board for IdeS in anti-GBM disease","u":"/media/press-releases/2015/hansa-medical-ab-announces-the-formation-of-a-medical-advisory-board-for-ides-in-anti-gbm-disease/"},{"d":"2015-01-27","n":"Hansa Medical appoints Göran Arvidson as CFO","u":"/media/press-releases/2015/hansa-medical-appoints-goran-arvidson-as-cfo/"},{"d":"2015-01-20","n":"Successful Phase 2 Study of IdeS in Highly Sensitized Dialysis Patients awaiting Kidney Transplantation","u":"/media/press-releases/2015/successful-phase-2-study-of-ides-in-highly-sensitized-dialysis-patients-awaiting-kidney-transplantation/"},{"d":"2015-01-15","n":"Hansa Medical financial reporting dates","u":"/media/press-releases/2015/hansa-medical-financial-reporting-dates/"},{"d":"2015-01-07","n":"Last patient included in IdeS clinical Phase II study","u":"/media/press-releases/2015/last-patient-included-in-ides-clinical-phase-ii-study/"},{"d":"2014-11-25","n":"Fredrik Lindgren appointed new President and CEO of Hansa Medical","u":"/media/press-releases/2014/fredrik-lindgren-appointed-new-president-and-ceo-of-hansa-medical/"},{"d":"2014-11-11","n":"Genovis AB files complaint for patent infringement by Promega Inc.","u":"/media/press-releases/2014/genovis-ab-files-complaint-for-patent-infringement-by-promega-inc/"},{"d":"2014-10-01","n":"Birgit Stattin Norinder appointed new chairman of Hansa Medical’s board of directors","u":"/media/press-releases/2014/birgit-stattin-norinder-appointed-new-chairman-of-hansa-medicals-board-of-directors/"},{"d":"2014-09-29","n":"Bo Håkansson has passed away","u":"/media/press-releases/2014/bo-hakansson-has-passed-away/"},{"d":"2014-08-18","n":"The Hansa Medical candidate drug IdeS has enabled successful kidney transplantation","u":"/media/press-releases/2014/the-hansa-medical-candidate-drug-ides-has-enabled-successful-kidney-transplantation/"},{"d":"2014-07-25","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2014","u":"/media/press-releases/2014/hansa-medical-ab-publ---interim-report-january-1---june-30-2014/"},{"d":"2014-07-09","n":"Phase II IdeS-study initiated in Uppsala","u":"/media/press-releases/2014/phase-ii-ides-study-initiated-in-uppsala/"},{"d":"2014-07-01","n":"Hansa Medical to present IdeS at the 2014 World Transplant Congress in San Francisco, July 27","u":"/media/press-releases/2014/hansa-medical-to-present-ides-at-the-2014-world-transplant-congress-in-san-francisco-july-27/"},{"d":"2014-06-11","n":"Hansa Medical to present IdeS at the 2014 BIO International Convention in San Diego, USA, on June 26","u":"/media/press-releases/2014/hansa-medical-to-present-ides-at-the-2014-bio-international-convention-in-san-diego-usa-on-june-26/"},{"d":"2014-05-06","n":"Swedish Medical Products Agency approves Hansa Medical’s clinical Phase II-study application with IdeS","u":"/media/press-releases/2014/swedish-medical-products-agency-approves-hansa-medicals-clinical-phase-ii-study-application-with-ides/"},{"d":"2014-05-02","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2014/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2014-04-30","n":"Hansa Medical’s Annual Report of 2013 has been published (In Swedish)","u":"/media/press-releases/2014/hansa-medicals-annual-report-of-2013-has-been-published-in-swedish/"},{"d":"2014-04-11","n":"Hansa Medical’s rights issue oversubscribed","u":"/media/press-releases/2014/hansa-medicals-rights-issue-oversubscribed/"},{"d":"2014-04-10","n":"Hansa Medical to present IdeS at the World Orphan Drug Congress USA, April 24 in Washington D.C.","u":"/media/press-releases/2014/hansa-medical-to-present-ides-at-the-world-orphan-drug-congress-usa-april-24-in-washington-dc/"},{"d":"2014-04-10","n":"Hansa Medical appoints Medical Advisory Board","u":"/media/press-releases/2014/hansa-medical-appoints-medical-advisory-board/"},{"d":"2014-04-03","n":"The 2014 Annual General Meeting of Hansa Medical has been rescheduled to June 3","u":"/media/press-releases/2014/the-2014-annual-general-meeting-of-hansa-medical-has-been-rescheduled-to-june-3/"},{"d":"2014-03-19","n":"Hansa Medical publishes prospectus regerading preferential rights issue at SEK 37 million","u":"/media/press-releases/2014/hansa-medical-publishes-prospectus-regerading-preferential-rights-issue-at-sek-37-million/"},{"d":"2014-03-05","n":"Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2014/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2014-03-03","n":"Hansa Medical files application for phase II-study with IdeS","u":"/media/press-releases/2014/hansa-medical-files-application-for-phase-ii-study-with-ides/"},{"d":"2014-02-14","n":"Notice of extraordinary meeting of shareholders in Hansa Medical AB (publ)","u":"/media/press-releases/2014/notice-of-extraordinary-meeting-of-shareholders-in-hansa-medical-ab-publ/"},{"d":"2014-02-14","n":"Funding of the Phase II study with IdeS secured","u":"/media/press-releases/2014/funding-of-the-phase-ii-study-with-ides-secured/"},{"d":"2014-02-05","n":"Year-end report 2013","u":"/media/press-releases/2014/year-end-report-2013/"},{"d":"2014-01-27","n":"Succesfully completed Phase I study with IdeS","u":"/media/press-releases/2014/succesfully-completed-phase-i-study-with-ides/"},{"d":"2013-11-18","n":"Hansa Medical receives SEK 3.4 million grant from VINNOVA to carry out Phase II study with IdeS","u":"/media/press-releases/2013/hansa-medical-receives-sek-34-million-grant-from-vinnova-to-carry-out-phase-ii-study-with-ides/"},{"d":"2013-11-06","n":"U.S Department of Health and Human Services  reports critical need for better prediction of severe sepsis.","u":"/media/press-releases/2013/us-department-of-health-and-human-services--reports-critical-need-for-better-prediction-of-severe-sepsis/"},{"d":"2013-11-05","n":"Hansa Medical and Axis-Shield report most promising results from pivotal clinical trial with HBP-analysis","u":"/media/press-releases/2013/hansa-medical-and-axis-shield-report-most-promising-results-from-pivotal-clinical-trial-with-hbp-analysis/"},{"d":"2013-11-04","n":"All healthy subjects have been treated in Hansa Medicals´ Phase I-study with IdeS","u":"/media/press-releases/2013/all-healthy-subjects-have-been-treated-in-hansa-medicals-phase-i-study-with-ides/"},{"d":"2013-10-03","n":"Hansa Medical strengthens its liquidity","u":"/media/press-releases/2013/hansa-medical-strengthens-its-liquidity/"},{"d":"2013-07-25","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2013","u":"/media/press-releases/2013/hansa-medical-ab-publ---interim-report-january-1---june-30-2013/"},{"d":"2013-05-15","n":"Promising research results with EndoS published in PNAS","u":"/media/press-releases/2013/promising-research-results-with-endos-published-in-pnas/"},{"d":"2013-05-07","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2013","u":"/media/press-releases/2013/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2013/"},{"d":"2013-04-15","n":"Hansa Medical’s annual report of 2012 (in Swedish) has been published","u":"/media/press-releases/2013/hansa-medicals-annual-report-of-2012-in-swedish-has-been-published/"},{"d":"2013-03-28","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2013/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2013-03-22","n":"Hansa Medical enters liquidity provider agreement with Erik Penser Bankaktiebolag","u":"/media/press-releases/2013/hansa-medical-enters-liquidity-provider-agreement-with-erik-penser-bankaktiebolag/"},{"d":"2013-03-21","n":"The Annual General Meeting of Hansa Medical has been rescheduled to May 6, 2013","u":"/media/press-releases/2013/the-annual-general-meeting-of-hansa-medical-has-been-rescheduled-to-may-6-2013/"},{"d":"2013-03-18","n":"Hansa Medical’s clinical Phase I study with IdeS has been initiated","u":"/media/press-releases/2013/hansa-medicals-clinical-phase-i-study-with-ides-has-been-initiated/"},{"d":"2013-02-07","n":"Year-end report 2012","u":"/media/press-releases/2013/year-end-report-2012/"},{"d":"2013-02-06","n":"Hansa Medical receive approval from Swedish Medical Products Agency to begin clinical Phase I study with IdeS","u":"/media/press-releases/2013/hansa-medical-receive-approval-from-swedish-medical-products-agency-to-begin-clinical-phase-i-study-with-ides/"},{"d":"2012-12-18","n":"Hansa Medical development partner Axis-Shield Diagnostics launches CE-marked ELISA assay for measurement of HBP","u":"/media/press-releases/2012/hansa-medical-development-partner-axis-shield-diagnostics-launches-ce-marked-elisa-assay-for-measurement-of-hbp/"},{"d":"2012-11-14","n":"HBP-assay website launched","u":"/media/press-releases/2012/hbp-assay-website-launched/"},{"d":"2012-07-26","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2012","u":"/media/press-releases/2012/hansa-medical-ab-publ---interim-report-january-1---june-30-2012/"},{"d":"2012-05-15","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2012","u":"/media/press-releases/2012/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2012/"},{"d":"2012-04-23","n":"Hansa Medical’s annual report of 2011 (in Swedish) has been published","u":"/media/press-releases/2012/hansa-medicals-annual-report-of-2011-in-swedish-has-been-published/"},{"d":"2012-03-22","n":"Hansa Medical’s rights issue with preferential rights has been completed","u":"/media/press-releases/2012/hansa-medicals-rights-issue-with-preferential-rights-has-been-completed/"},{"d":"2012-03-20","n":"HMD-301 for diagnosis of Urinary Tract Infection: novel clinical results published","u":"/media/press-releases/2012/hmd-301-for-diagnosis-of-urinary-tract-infection-novel-clinical-results-published/"},{"d":"2012-03-14","n":"Hansa Medical granted patents in the United States and Europe for the medical use of IdeS","u":"/media/press-releases/2012/hansa-medical-granted-patents-in-the-united-states-and-europe-for-the-medical-use-of-ides/"},{"d":"2012-03-08","n":"Hansa Medical has been granted European patent for diagnostic method HMD-301","u":"/media/press-releases/2012/hansa-medical-has-been-granted-european-patent-for-diagnostic-method-hmd-301/"},{"d":"2012-02-15","n":"Annual General Meeting of Hansa Medical rescheduled to May 14, 2012","u":"/media/press-releases/2012/annual-general-meeting-of-hansa-medical-rescheduled-to-may-14-2012/"},{"d":"2012-02-09","n":"Year-End Release 2011","u":"/media/press-releases/2012/year-end-release-2011/"},{"d":"2012-01-25","n":"Directed new share issue by Hansa Medical AB (publ) completed","u":"/media/press-releases/2012/directed-new-share-issue-by-hansa-medical-ab-publ-completed/"},{"d":"2012-01-10","n":"Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2012/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2011-12-14","n":"Notice of extraordinary meeting of shareholders in Hansa Medical AB (publ)","u":"/media/press-releases/2011/notice-of-extraordinary-meeting-of-shareholders-in-hansa-medical-ab-publ/"},{"d":"2011-12-08","n":"Hansa Medical executes a directed new share issue to NXT2B immediately followed by a guaranteed preferential rights issue – In total MSEK 46 is raised","u":"/media/press-releases/2011/hansa-medical-executes-a-directed-new-share-issue-to-nxt2b-immediately-followed-by-a-guaranteed-preferential-rights-issue--in-total-msek-46-is-raised/"},{"d":"2011-12-08","n":"Hansa Medical closes preclinical research project and focuses on clinical development of enzyme based treatment of rare diseases","u":"/media/press-releases/2011/hansa-medical-closes-preclinical-research-project-and-focuses-on-clinical-development-of-enzyme-based-treatment-of-rare-diseases/"},{"d":"2011-07-28","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2011","u":"/media/press-releases/2011/hansa-medical-ab-publ---interim-report-january-1---june-30-2011/"},{"d":"2011-06-23","n":"Bo Håkansson increases ownership in Hansa Medical AB (publ) through acquisition of more than 1 million shares","u":"/media/press-releases/2011/bo-hakansson-increases-ownership-in-hansa-medical-ab-publ-through-acquisition-of-more-than-1-million-shares/"},{"d":"2011-06-17","n":"Hansa Medical’s rights issue amounting SEK 29 million has been oversubscribed","u":"/media/press-releases/2011/hansa-medicals-rights-issue-amounting-sek-29-million-has-been-oversubscribed/"},{"d":"2011-06-01","n":"Hansa Medical arranges information meetings in Malmö and Stockholm","u":"/media/press-releases/2011/hansa-medical-arranges-information-meetings-in-malmo-and-stockholm/"},{"d":"2011-05-23","n":"Hansa Medical publishes financial information from its prospectus regarding the new share issue","u":"/media/press-releases/2011/hansa-medical-publishes-financial-information-from-its-prospectus-regarding-the-new-share-issue/"},{"d":"2011-05-23","n":"Hansa Medical’s prospectus for the new share issue of MSEK 29 has been published","u":"/media/press-releases/2011/hansa-medicals-prospectus-for-the-new-share-issue-of-msek-29-has-been-published/"},{"d":"2011-05-23","n":"Hansa Medical establish agreement on subscription commitment and issuing guarantee","u":"/media/press-releases/2011/hansa-medical-establish-agreement-on-subscription-commitment-and-issuing-guarantee/"},{"d":"2011-05-13","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2011","u":"/media/press-releases/2011/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2011/"},{"d":"2011-05-11","n":"HMD-301 for diagnosis of bacterial meningitis: novel clinical results published","u":"/media/press-releases/2011/hmd-301-for-diagnosis-of-bacterial-meningitis-novel-clinical-results-published/"},{"d":"2011-04-28","n":"Hansa Medical’s annual report of 2010 (In Swedish) now available at corporate website","u":"/media/press-releases/2011/hansa-medicals-annual-report-of-2010-in-swedish-now-available-at-corporate-website/"},{"d":"2011-04-11","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2011/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2011-04-11","n":"Hansa Medicals’ Board of Directors recommend AGM to issue new shares to raise SEK 29 million","u":"/media/press-releases/2011/hansa-medicals-board-of-directors-recommend-agm-to-issue-new-shares-to-raise-sek-29-million/"},{"d":"2011-04-01","n":"Annual General Meeting of Hansa Medical rescheduled to May 12, 2011","u":"/media/press-releases/2011/annual-general-meeting-of-hansa-medical-rescheduled-to-may-12-2011/"},{"d":"2011-03-23","n":"Hansa Medical terminates liquidity provider agreement","u":"/media/press-releases/2011/hansa-medical-terminates-liquidity-provider-agreement/"},{"d":"2011-03-21","n":"Hansa Medical and Axis-Shield begin multi-centre clinical study of HBP assay for diagnosis of severe sepsis","u":"/media/press-releases/2011/hansa-medical-and-axis-shield-begin-multi-centre-clinical-study-of-hbp-assay-for-diagnosis-of-severe-sepsis/"},{"d":"2011-02-10","n":"Year-End Release 2010","u":"/media/press-releases/2011/year-end-release-2010/"},{"d":"2011-01-10","n":"Hansa Medicals' development partner Axis-Shield signs option agreement with Bio-Rad Laboratories for commercialisation of Heparin Binding Protein","u":"/media/press-releases/2011/hansa-medicals-development-partner-axis-shield-signs-option-agreement-with-bio-rad-laboratories-for-commercialisation-of-heparin-binding-protein/"},{"d":"2010-09-20","n":"Hansa Medical AB receives milestone payment for achieving a strong alpha-11 patent portfolio","u":"/media/press-releases/2010/hansa-medical-ab-receives-milestone-payment-for-achieving-a-strong-alpha-11-patent-portfolio/"},{"d":"2010-09-06","n":"Hansa Medical AB enters license agreement with Human Genome Sciences Inc.","u":"/media/press-releases/2010/hansa-medical-ab-enters-license-agreement-with-human-genome-sciences-inc/"},{"d":"2010-07-29","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2010","u":"/media/press-releases/2010/hansa-medical-ab-publ---interim-report-january-1---june-30-2010/"},{"d":"2010-04-30","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2010","u":"/media/press-releases/2010/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2010/"},{"d":"2010-04-20","n":"Final outcome of Hansa Medical’s rights issue","u":"/media/press-releases/2010/final-outcome-of-hansa-medicals-rights-issue/"},{"d":"2010-04-16","n":"Hansa Medical’s rights issue oversubscribed","u":"/media/press-releases/2010/hansa-medicals-rights-issue-oversubscribed/"},{"d":"2010-04-15","n":"Hansa Medical’s Annual Report 2009 (In Swedish) now available online","u":"/media/press-releases/2010/hansa-medicals-annual-report-2009-in-swedish-now-available-online/"},{"d":"2010-04-15","n":"Hansa Medical’s Annual Report 2009 (In Swedish) now available online","u":"/media/press-releases/2010/hansa-medicals-annual-report-2009-in-swedish-now-available-online-2010-04-15/"},{"d":"2010-03-26","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2010/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2010-03-19","n":"Hansa Medical rights issue prospectus in Swedish has been published","u":"/media/press-releases/2010/hansa-medical-rights-issue-prospectus-in-swedish-has-been-published/"},{"d":"2010-03-04","n":"Hansa Medical to implement guaranteed rights issue amounting to SEK 27 million","u":"/media/press-releases/2010/hansa-medical-to-implement-guaranteed-rights-issue-amounting-to-sek-27-million/"},{"d":"2010-02-10","n":"Year-End Release 2009","u":"/media/press-releases/2010/year-end-release-2009/"},{"d":"2009-09-28","n":"Clinical research results with HMD-301 published in Clinical Infectious Diseases","u":"/media/press-releases/2009/clinical-research-results-with-hmd-301-published-in-clinical-infectious-diseases/"},{"d":"2009-07-30","n":"Interim report January 1 – June 30, 2009","u":"/media/press-releases/2009/interim-report-january-1--june-30-2009/"},{"d":"2009-06-22","n":"Hansa Medical and Inverness Medical Innovations launch partnership agreement for the development of biopharmaceuticals to treat rheumatoid arthritis","u":"/media/press-releases/2009/hansa-medical-and-inverness-medical-innovations-launch-partnership-agreement-for-the-development-of-biopharmaceuticals-to-treat-rheumatoid-arthritis/"},{"d":"2009-06-15","n":"Hansa Medical and Axis-Shield enter development and license agreement regarding novel biomarker for severe sepsis","u":"/media/press-releases/2009/hansa-medical-and-axis-shield-enter-development-and-license-agreement-regarding-novel-biomarker-for-severe-sepsis/"},{"d":"2009-05-07","n":"Hansa Medical receives financing from VINNOVA for research project","u":"/media/press-releases/2009/hansa-medical-receives-financing-from-vinnova-for-research-project/"},{"d":"2009-04-30","n":"Press release from the 2009 Annual General Meeting of Hansa Medical AB","u":"/media/press-releases/2009/press-release-from-the-2009-annual-general-meeting-of-hansa-medical-ab/"},{"d":"2009-04-15","n":"Hansa Medical’s Election Committee moves for re-election of the Board","u":"/media/press-releases/2009/hansa-medicals-election-committee-moves-for-re-election-of-the-board/"},{"d":"2009-04-05","n":"Annual Report 2008 (In Swedish)","u":"/media/press-releases/2009/annual-report-2008-in-swedish/"},{"d":"2009-04-03","n":"Hansa Medical divests research project","u":"/media/press-releases/2009/hansa-medical-divests-research-project/"},{"d":"2009-03-31","n":"Notice of the Annual General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2009/notice-of-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2009-02-10","n":"Year-End Release 2008","u":"/media/press-releases/2009/year-end-release-2008/"},{"d":"2008-11-24","n":"Hansa Medical changes certified adviser","u":"/media/press-releases/2008/hansa-medical-changes-certified-adviser/"},{"d":"2008-08-21","n":"Interim report January 1 – June 30, 2008","u":"/media/press-releases/2008/interim-report-january-1--june-30-2008/"},{"d":"2008-05-15","n":"Hansa Medical redeems convertible loan – positive earnings effect of SEK 15.1 M","u":"/media/press-releases/2008/hansa-medical-redeems-convertible-loan--positive-earnings-effect-of-sek-151-m/"},{"d":"2008-05-08","n":"Press release from the Annual General Meeting of Hansa Medical AB (publ) on May 7, 2008","u":"/media/press-releases/2008/press-release-from-the-annual-general-meeting-of-hansa-medical-ab-publ-on-may-7-2008/"},{"d":"2008-04-23","n":"Annual Report 2007 (In Swedish)","u":"/media/press-releases/2008/annual-report-2007-in-swedish/"},{"d":"2008-04-08","n":"Notice of the Annual General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2008/notice-of-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2008-02-28","n":"Year-End Release 2007","u":"/media/press-releases/2008/year-end-release-2007/"},{"d":"2008-01-15","n":"Hansa Medical acquires all assets in Cartela AB","u":"/media/press-releases/2008/hansa-medical-acquires-all-assets-in-cartela-ab/"},{"d":"2007-11-20","n":"Chairman of the Board acquires shares","u":"/media/press-releases/2007/chairman-of-the-board-acquires-shares/"},{"d":"2007-10-17","n":"Hansa Medical listed on First North","u":"/media/press-releases/2007/hansa-medical-listed-on-first-north/"},{"d":"2007-10-12","n":"Hansa Medical approved for trading on First North","u":"/media/press-releases/2007/hansa-medical-approved-for-trading-on-first-north/"},{"d":"2007-10-03","n":"Hansa Medical’s new share issue totaling SEK 38 M fully subscribed","u":"/media/press-releases/2007/hansa-medicals-new-share-issue-totaling-sek-38-m-fully-subscribed/"}]